؉ T cell responses against intracellular infectious agents are initiated upon recognition of pathogen-derived peptides presented at the cell surface of infected cells in the context of MHC class I molecules. Among the major MHC class I loci, HLA-B is the swiftest evolving and the most polymorphic locus. Additionally, responses restricted by HLA-B molecules tend to be dominant, and most associations with susceptibility or protection against infectious diseases have been assigned to HLA-B alleles. To assess whether the differences in responses mediated via two major HLA class I loci, HLA-B and HLA-A, may already begin at the Ag presentation level, we have analyzed the diversity and binding affinity of their peptide repertoire by making use of curated pathogen-derived epitope data retrieved from the Immune Epitope Database and Analysis Resource, as well as in silico predicted epitopes. In contrast to our expectations, HLA-B alleles were found to have a less diverse peptide repertoire, which points toward a more restricted binding motif, and the respective average peptide binding affinity was shown to be lower than that of HLA-A-restricted epitopes. This unexpected observation gives rise to new hypotheses concerning the mechanisms underlying immunodominance of CD8 ؉ T cell responses.
M HC class I molecules play a crucial role in initiating potentially protective immune responses by presenting intracellular pathogen-derived peptides to CD8
ϩ T cells and thus targeting infected cells for elimination. The enormous polymorphism of MHC class I genes (1) is most likely pathogen-driven (2-6). Still, this selection pressure does not seem to be acting homogeneously in all major class I loci. Among the homologous major HLA class I loci, HLA-B seems to possess some distinctive characteristics. HLA-B is the most diverse class I locus and the most polymorphic gene of the human genome (7) . Indeed, it seems to be the most rapidly evolving locus and it has an exceptional rate of recombination (8) , suggesting that it is under the strongest selective pressure. The latter has also been highlighted by Prugnolle and colleagues, who have shown that the positive correlation between variation at the classical HLA class I loci and pathogen richness is strongest for HLA-B (5). Furthermore, HLA-B-restricted pathogen-derived epitopes seem to be more frequently targeted by CD8 ϩ T cells than those presented on HLA-A. This has been shown for viral pathogens such as HIV, EBV, influenza, and CMV (9 -12), as well as for an intracellular bacterial pathogen, Mycobacterium tuberculosis (13) . Additionally, HLA-B-dictated T cell responses seem to be of higher magnitude (10, 13, 14) and have been described to influence infectious disease course and outcome. In HIV infection, a specific group of B alleles (e.g., B*3502, B*3503, B*3504, B*5301, B*5802) has been associated with fast progression toward AIDS (9, 15, 16) , while others, like B27, B57, and B*5801, are commonly referred to as "protective", as they are associated with a longer AIDS-free survival period or other favorable features related to a better prognosis, such as a lower viral load (17, 18) . Kiepiela and colleagues have also demonstrated a broader dominance of B alleles in influencing HIV disease outcome due to their impact on viral setpoint and CD4
ϩ T cell counts (9) . Also, in hepatitis C virus infection, HLA-B27 seems to be the allele most significantly associated with spontaneous viral clearance (19) . Furthermore, the association of B53 with protection from severe malaria has most likely contributed to its high frequencies in West Africa (20) . Although the associations of HLA-B molecules with disease outcome suggest a fundamental role of CD8 ϩ T cells in responding against intracellular pathogens upon recognition of peptide-HLA-B complexes in infected cells, they may also be a consequence of engagement of HLA-B by NK cell receptors and subsequent impact on NK cell function (17, 21) .
The three features of HLA-B molecules mentioned abovehigh polymorphism, trend to induce immunodominant CD8 ϩ T cell responses, and association with disease susceptibility or protection-are most likely related: HLA-B alleles may be major determinants, "for good or for bad", of the effectiveness of immune responses against pathogens because the responses they elicit are dominant. This immunodominance may, among others, stem from differences in presentation of antigenic peptides via HLA-B or from a more amplified qualitative and/or quantitatively response from specific CD8 ϩ T cells to HLA-B-restricted epitopes (22, 23) . Intrinsic differences in the amount/diversity and binding affinity (and thus stability at the cell surface) of the peptides they present might provide the grounds for their superiority. These issues on peptide presentation have been addressed in this study. We envisioned that HLA-B alleles would have a broader peptide repertoire than that of HLA-A alleles, inducing a more diverse CTL response, and that the epitopes would be of higher affinity, ensuring a longer stimulation of T cell responses and thus further accounting for the immunodominance observed. Surprisingly, our results show that, in contrast with our initial expectations, HLA-B alleles may actually have a more restricted binding motif, they may present fewer peptides than do their HLA-A homologs, and their binding affinity tends to be lower. How these particular HLA-B features may lead to immunodominance is thus far unclear, yet they open up new hypotheses for the effects of Ag presentation on immunodominance.
Materials and Methods

Epitope data
All epitopes previously shown to bind to HLA molecules were downloaded as an XML file from the Immune Epitope Database and Analysis Resource (IEDB 3 ; www.immuneepitope.org/;downloads were made in May 2007). As the chance of two different proteins sharing a peptide larger than a 7-mer seems to be maximally 2-3% (24), all epitopes with fewer than seven amino acids similarity were kept as unique epitopes for each HLA allele. In total, 11,878 unique epitopes for 19 HLA-A alleles and 2353 unique epitopes for 16 HLA-B alleles having a length varying from 6 to 16 amino acids were obtained from IEDB as our experimental binding data.
The affinity of most (Ͼ98%) HLA-A and B epitopes in IEDB was measured by two experimental methods. The first method (competition assays where purified MHC and radioactive labeling are used) covered 94% of HLA-A epitopes and 78% of HLA-B epitopes, while the second method (association studies where purified MHC and fluorescence labeling are used) covered 5% HLA-A epitopes and 21% HLA-B epitopes. Eighty-five epitopes were measured by both methods. Using this overlap data, we found a significant correlation of measured affinities by both methods ( p ϭ 0.0001).
Genomic data
Sequences of the human proteome as a resource of self-peptides, 13 common bacteria, and 17 common virus proteomes (supplemental Table S1 ) 4 as resources of pathogenic (non-self) peptides were downloaded from the European Bioinformatics Institute web site (www.ebi.ac.uk/; downloads were made in Oct 2006). Peptide fragments of 9 or 10 amino acids long were generated from each protein in all proteomes using all positions as possible first positions. All redundant 9-mers or 10-mers that are present more than one time in a proteome or contain any ambiguous amino acids such as "B, Z, X" were deleted from the dataset. In the end, a total of 10,941,519 unique human 9-mers, 11,647,396 unique bacterial 9-mers, and 57,433 unique viral 9-mers were retrieved from these proteomes.
Two types of sequence modifications in the original proteomes were applied in this study: 1) protein shuffling, that is, shuffling residues within a protein by keeping the frequency of amino acids and the length of the protein intact; and 2) generating artificial proteomes, that is, artificial proteomes were generated by using a uniform amino acid distribution (i.e., frequency of each amino acid is 0.05) without changing the size of original proteome. All of these sequence modifications were performed by Perl programming.
HLA peptide binding predictions
There are at present several HLA peptide binding predictors, such as the polynomial method (25) , artificial neural networks (26) , the BIMAS algorithm (27) , a classification and regression tree (28) , an additive method (29) , and the stabilized matrix method (SMM) (30) . The performance of these algorithms to identify new epitopes has recently been benchmarked on experimental data (31) . In general, artificial neural networks and SMM methods were found to be superior to the other ones. Moreover, the results of these large-scale benchmark studies show that the accuracy of HLA peptide binding prediction algorithms has increased over time to such an extent that the correlation between predicted and measured binding affinity is as good as the correlation between measurements from different laboratories (31) . Another demonstration of how powerful these predictions are is a study by Schellens et al. (7), who identified 18 new CTL epitopes out of a set of 22 predicted CTL epitopes using artificial neural networks-based HLA peptide binding predictors. This suggests that the specificity of the predictors can be as high as 80%.
SMM was chosen as the main prediction method in this project because it has the most broad HLA coverage at the time this project was initiated. For each HLA molecule a specific SMM matrix was generated using the experimental binding data. The details of this algorithm are given elsewhere (30) . We downloaded SMM prediction software and training datasets from IEDB (mhcbindingpredictions.immuneepitope.org/) and generated scoring matrices ourselves. For 9-mer prediction, 19 HLA-A and 15 HLA-B SMM matrices were generated, while for 10-mer prediction 14 HLA-A and 5 HLA-B matrices were generated because of training data limitation.
As suggested by Ruppert et al. (32) , an IC 50 threshold of 500 nM was used to distinguish binding peptides from nonbinding peptides.
Thus, the binding fraction of a particular HLA allele was calculated as: binding fraction ϭ (no. of n-mers/no. of all n-mers) (n ϭ 9 or 10).
Shannon entropy calculation and binding motif visualization
The Shannon entropy (33) was calculated to measure the degree of variability in HLA binding motifs. This entropy measure is defined as:
where E(i) is the Shannon entropy at position i, and q i is the probability that a particular amino acid occurs at position i in the alignment. 
Results
HLA-A alleles present a larger set of epitopes than do HLA-B alleles
To explore the differences in the epitope repertoire of HLA molecules, publicly available experimental epitope data were analyzed. At present, IEDB is the most complete database for experimentally verified epitopes. All epitopes that can bind to HLA-A or HLA-B alleles were retrieved from IEDB (downloads were made in October 2006). The number of known epitopes per allele shows a very skewed distribution: for the common alleles, thousands of epitopes are identified, while for the rare alleles as few as only one epitope is found. In IEDB the average number of unique epitopes for each HLA-A allele is 216 (median, 15; range, 1-2341) and the average number of unique epitopes for each HLA-B allele is 37 (median, 8; range, 1-399). Thus, the diversity of HLA-A binding epitopes seems to be larger than that of HLA-B. After excluding alleles having fewer than 20 epitopes, we calculated the epitope length distribution for 19 HLA-A and 16 HLA-B alleles (Fig. 1) . The epitope length distributions of HLA-A and HLA-B alleles were very similar and showed a marked preference to bind epitopes of length 9 (9-mers) or length 10 (10-mers) (Fig. 1) . For the rest of the paper this data set is used and referred to as "experimental binding data".
The experimental data might have some biases, for example, due to dominance of certain HLA molecules like HLA-A*02 (www. allelefrequencies.net). Alternatively, one can screen proteomes for epitopes restricted by every HLA molecule for which prediction methods are available to determine epitope repertoires. We based our analysis on SMM predictions because at the time we initialized our study the SMM method had the largest allele coverage. Using publicly available software and data, we generated 19 HLA-A and 15 HLA-B SMM scoring matrices and predicted the binding affinity of all possible 9-mers from the human, bacterial, and viral proteomes (as explained in Materials and Methods). SMM matrices assign to each 9-mer HLA pair an IC 50 value that indicates the binding affinity. The lower IC 50 value implies the higher binding affinity of the 9-mer to a certain HLA molecule. As suggested earlier (32) , an IC 50 threshold of 500 nM was used to distinguish binding 9-mers from nonbinding 9-mers. We defined the binding fraction as the fraction of SMM-predicted binding 9-mers on an HLA molecule among all possible 9-mers in a proteome and used this as a parameter to indicate the epitope diversity of the HLA molecule. Fig. 2 shows that on average the binding fraction of HLA-A alleles is ϳ5%, which is significantly higher than the average binding fraction of HLA-B alleles (2%) in the human proteome ( Fig. 2 ; p Ͻ 0.001, Mann-Whitney U test). Similar results were obtained for viral 9-mers and bacterial 9-mers (Fig. 2) .
Changing the IC 50 threshold (using 50 nM and 5000 nM instead of 500 nM) or excluding two alleles that are either too generic (A*3002, with a binding fraction Ͼ20%) or too specific (B*0801, which does not have a predicted binder in many viral proteomes) did not change our results (results not shown). Thus, HLA-A alleles seem to bind 2-fold more peptides than do HLA-B alleles. We repeated the same prediction scheme for 10-mers and found similar results (data not shown). Note that among HLA alleles there is a large variation in predicted binding fraction (data for individual alleles are shown in supplemental Fig. S1 ).
When we shuffled the protein sequences in different proteomes, or when we created artificial proteomes with equal amino acid frequencies (i.e., when the frequency of each amino acid is 0.05), the binding fraction of HLA-A alleles remained 2-fold higher than that of HLA-B alleles (supplemental Fig. S2 ). This result implies that sequence patterns or amino acid frequencies in different proteomes are not responsible for differences in epitope diversity between HLA-A and HLA-B molecules.
Surprisingly, HLA-A molecules were predicted to bind significantly fewer human 9-mers than pathogen-derived 9-mers ( p Ͻ 0.001, Mann-Whitney U test), which was not the case for HLA-B molecules (Fig. 2 ). This preference pattern was robust to shuffling of protein sequences, but it disappeared when we created artificial proteomes with equal amino acid frequencies. Apparently, very small differences in amino acid usage among human, viral, and bacterial proteomes (supplemental Fig. S3 ) may create a preference for presenting non-self.
Experimentally verified epitopes of a given HLA molecule are used to construct a SMM scoring matrix that can predict new epitopes of this HLA molecule (35) . The number of experimental epitopes used to construct SMM predictors, that is, the training set size, varies among different HLA molecules. To exclude the possibility that the low binding fraction of HLA-B alleles is due to small training sets, we plotted the predicted binding fraction vs training set size of each allele in supplemental Fig. S4 . Neither for human nor for pathogenic proteomes did we find a significant correlation ( p Ͼ 0.5), which suggests that the higher binding specificity of HLA-B molecules is not an artifact of the data size used to develop the predictors.
In summary, both experimental data and our in silico predictions suggest that the binding motif of HLA-B molecules is in general more restricted than that of HLA-A molecules, and therefore HLA-B molecules present a less diverse set of epitopes than do HLA-A molecules.
The binding affinity of HLA-A epitopes is significantly higher than that of HLA-B epitopes
Another factor that may affect the immunodominance of T cell responses is the binding affinity of peptides to HLA molecules (36) . We analyzed both experimental and predicted binding data to compare the binding affinity of HLA-A and HLA-B molecules.
All experimentally verified HLA-A and HLA-B epitopes that have an IC 50 value associated were retrieved from the IEDB database and are shown in Fig. 3 . In vitro-measured binding affinities of HLA-A epitopes are significantly higher than those of HLA-B epitopes ( p Ͻ 0.001, Mann-Whitney U test). The binding affinities of most epitopes in IEDB (94% HLA-A epitopes and 78% HLA-B epitopes) were measured using a competition (or equilibrium binding) assay with purified MHC molecules and radioactive labeling. By repeating our analysis for this subset to exclude a possible bias caused by experimental methods, we found that binding affinities of HLA-A epitopes are still significantly higher than those of HLA-B epitopes ( p Ͻ 0.001, Mann-Whitney U test). Thus, the differences we found between HLA-A and HLA-B epitope affinities are not due to the use of different experimental assays. We then analyzed the in silico-predicted binding affinities from the human, viral, and bacterial proteomes. To exclude a potential bias introduced by the 2-fold higher amount of predicted HLA-A epitopes as compared with those restricted by HLA-B alleles, we selected the top five predicted epitopes, with the highest predicted binding affinity, for each HLA molecule from each proteome. The average binding affinity of predicted HLA-A epitopes is significantly higher ( p Ͻ 0.001, Mann-Whitney U test) than that of predicted HLA-B epitopes (Fig. 3) . The results were confirmed by repeating the same analysis for the top 10 epitopes of each HLA molecule (results not shown).
Although the predicted binding affinities show the same tendency as the experimental data (Fig. 3) , one can argue that the predictions are not true validations of the experimental data, because they are not independent, that is, the prediction methods were trained on the available experimental data. To separate the experimental data as much as possible from the predictions, we used the following strategy: each time we chose three HLA-A and three HLA-B alleles randomly from all of the alleles where prediction methods were available. Then, we compared the predicted binding affinities for the randomly chosen three HLA-A and HLA-B alleles, while excluding the six alleles used in the prediction analysis from the experimental binding data and compared HLA-A and HLA-B binding affinities in the rest. In this way, the alleles (and thus the epitope data) tested using the experimental data and the predictions are nonoverlapping. We repeated this process 100 times, and in 92 cases we found that both the predicted and experimentally verified binding affinities of HLA-B alleles were significantly lower than those for HLA-A alleles. One can therefore conclude that the significant difference in binding affinities of HLA-A and HLA-B alleles found in the experimental data is further supported with our predictions.
Next we tested whether the higher binding affinity can be a result of lower specificity in HLA-A binding motifs. In Fig. 4 we plotted the binding fraction vs the binding affinity of the top five predicted epitopes for all HLA molecules in our in silico analysis. Interestingly, there is a significant positive correlation ( p Ͻ 0.001) between the binding fraction and the average peptide binding affinity of these alleles, which suggests that a less specific binding motif would imply the higher binding affinities.
In summary, HLA-A epitopes have significantly higher binding affinities than do HLA-B epitopes, and a significant positive correlation was found between the binding fraction and the binding affinity of HLA molecules.
HLA-A and HLA-B molecules have different restrictions in anchor residues
Sequence patterns in a cohort of epitopes specific for a certain HLA molecule define its binding motif (37) . Some positions of HLA binding motif (e.g., P2, P3, P5, P9), which are very important for epitope binding, were defined as anchor positions (38 -41) .
To explore if the difference in binding specificity of HLA-A and HLA-B molecules is due to their binding motifs, all 9-mer epitopes from our experimental binding data were used to measure the degree of variability at each position in terms of the Shannon entropy (33), as explained in Materials and Methods. The larger Shannon entropy indicates higher level of variation in a position. Only the sequence conservation in P2 and P9 was significantly different between HLA-A and HLA-B epitopes ( p Ͻ 0.001, Mann-Whitney U test; Fig. 5 ). Interestingly, P2 is the most conserved position for HLA-B alleles, while for HLA-A alleles P9 has the lowest Shannon entropy (Fig. 5) .
Classifying all HLA molecules by their 9-mer binding motif patterns, we observed three groups of binding motifs. Group 1 includes HLA alleles with binding motifs that have a similar level of conservation in P2 and P9, and it contains both HLA-A and HLA-B molecules. Group 2 contains only HLA-B molecules, defined by a markedly conserved P2. Group 3 encloses only HLA-A molecules, and these share a conservative P9 in their binding motifs. Supplemental Fig. S5 gives two examples for each of these three groups using sequence logos (see figure caption for explanation).
Thus, in general both HLA-A and HLA-B molecules are more conserved in their anchor residues (e.g., P2 and P9), where P2 is more important for HLA-B alleles and P9 is more important for HLA-A alleles.
Discussion
Immune responses restricted by HLA-B alleles to several pathogens have been previously shown to be immunodominant (9 -11, 13, 14) . Additionally, particular HLA-B alleles seem to be associated with either protection or susceptibility to infectious diseases (see reviews in Refs. [17] [18] [19] [20] . It has been suggested that this association of HLA-B molecules with a favorable disease outcome may derive from the fact that they are ligands for NK cell receptors, and thus may promote either NK cell lysis of infected cells or inhibit NK cell function and diminish chronic immune activation (17, 21) . Alternatively, the immunodominance of HLA-B-restricted CD8 ϩ T cell responses might be the underlying reason why particular HLA-B alleles of a given individual tend to determine the effectiveness of the immune responses that he/she mounts.
In this study, we undertook two approaches to evaluate if the immunodominance of HLA-B-restricted responses relates to the intrinsic Ag presentation features of these alleles in terms of diversity and binding affinity of the epitopes they present. First, we compared experimental data on pathogen-derived epitopes available in the IEDB database. Second, and to exclude for potential biases in the IEDB epitope set, we performed the same analysis on in silico-predicted peptides derived from proteomes of viruses, bacteria, and human genomes. This analysis did not include epitopes restricted by HLA-C alleles, given that these have been historically less studied, and thus the data are more scarce and, consequently, no good predictors are currently available.
Surprisingly, we show that HLA-B alleles present a less diverse set of epitopes, ϳ5-fold lower than that of HLA-A alleles (based on experimental data). This disparity does not seem to be exclusively explained by the large amount of peptides described to be presented by HLA-A2, and is narrower (around 2.5 fold) when derived from prediction data (Fig. 2) . The familiar notion that 9-mers are the most preferred MHC class I ligands (42, 43) can be confirmed in this analysis, and it holds true for both loci (Fig. 1) . Curiously, our predictions suggest that HLA-A alleles have a preference for foreign over self-epitopes, which does not hold true for HLA-B molecules (Fig. 2) and is lost when the subtle differences among amino acid frequencies are excluded (see supplemental Figs. S2 and S3).
High HLA peptide binding affinity is not strictly correlated with immunodominance (44) . Moreover, Assarsson et al. showed that dominant epitopes might have lower affinities than subdominant epitopes (36) . In line with these findings, we found that the average binding affinity of epitopes restricted by HLA-B alleles is significantly lower than that of HLA-A peptides, in both experimental and predicted data (Fig. 3) . This might reflect a tendency for HLA-B molecules to be less dependent on tapasin-ERp57, a complex involved in editing the peptide cargo of MHC class I in favor of complexes with longer cell surface half-lives enclosing epitopes of higher binding affinity (45) (46) (47) (48) . In fact, thus far only B alleles have been shown to associate poorly with this chaperone, among which B27 and B*4405 (48 -50) . HLA dependence on tapasin seems to be dictated by polymorphisms at residues 116 and 114 located at the base of the F pocket of the binding cleft, which accommodates the peptide C terminus (48) , and the complex has been proposed to act by disrupting peptide-MHC class I complex formation until high-affinity peptides are bound (47) .
Interestingly, binding fraction and binding affinity seem to be positively correlated (Fig. 4) . HLA-A alleles seem to have a more permissive binding motif, where the most conserved residue is the C-terminal ( Fig. 5 and supplemental Fig. S5) . Consequently, the chance of finding peptides that fit their looser requirements is higher and will account for a larger pool of possible binders, from which the high-affinity peptides may be selected. Conversely, the binding motif of HLA-B alleles appears to be more restricted, especially in P2 (Fig. 5 and supplemental Fig. S5 ). In accordance, the information content for P2 of HLA-B epitopes is significantly higher ( p ϭ 0.017, Mann-Whitney U test) than that of the best conserved position of HLA-A, the C terminus. Thus, there is a narrower probability that the small proteome of pathogens will enclose sequences that would perfectly conform to HLA-B prerequisites. As a result, the peptides loaded in HLA-B complexes might frequently be suboptimal.
Another factor that determines the available peptides for each HLA is the specificity of the proteasome. Kesmir et al. have shown that the immunoproteasome has co-evolved with human MHC molecules, thus optimizing the process of Ag presentation (51) . We, therefore, plan to test next if especially HLA-A alleles have co-evolved with the proteasome, and thus have "designed" their F pocket as to favor the C terminus amino acids defined by the cleavage patterns of the catalytic subunits, while HLA-B alleles, evolving faster, may have a more variable F pocket and not so strict requirements for the C-terminal amino acids.
In summary, HLA-B alleles seem to present fewer peptides to CD8 ϩ T cells, which is consistent with a more restricted binding motif, and epitope binding affinity seems to be lower as compared with their HLA-A counterparts. Note that experimental data on binding affinity are generally determined in vitro using synthetic peptides derived from the protein sequence under study, rather than from naturally processed peptides. The in silico analysis, which we herein use to exclude possible sampling biases in the experimental data, was therefore also performed for all possible 9-mers, and it does not take into account the limiting steps of Ag processing (efficiency of proteasome cleavage, TAP transport, Nterminal trimming). Despite the lack of data on naturally processed peptides, our results, although unexpected and counterintuitive, call for novel hypotheses to explain why HLA-B alleles are associated with immunodominance.
First, if epitopes indeed bind with higher affinity to HLA-A molecules, these more stable complexes might remain longer at the cell surface. Stimulation of cognate T cells will thus occur longer and may potentially lead to exhaustion of these responses, especially in cases of chronic infection and, thus, Ag persistence. This would be in agreement with the findings of Harari and colleagues, who have shown that HLA-A-restricted epitopes drive high-avidity T cell responses by CTLs that have high expression of the exhaustion marker programmed death (PD)-1 (52) . As these highavidity T cells will be preferentially deleted (53) (54) (55) , the "surviving" HLA-B-restricted responses would become dominant. In contrast, Almeida and coworkers (56) have found HLA-B T cell responses to be of higher avidity during HIV infection. Still, the highest avidity response tested, although showing signs of higher clonal turnover and some features of senescence, was polyfunctional and still seemed to be actively involved in controlling HIV infection.
Second, because the pool of B epitopes is less diverse, the Ag "density" could be higher for B-restricted ligands; that is, HLA-B alleles would present epitopes more abundantly (assuming identical A and B expression at the cell surface). As such, the chance that a responsive B-restricted CD8 ϩ T cell would see its ligand would then be increased, and clones responding to these Ags would preferentially expand.
Third, one can envision that the difference in immunodominance may already be defined at the precursor level. In two studies comparing immunodominant and subdominant responses to lymphocytic choriomeningitis virus in mice, differences could be explained by a higher precursor frequency of the former (44, 57) . Most interestingly, a recent paper by Obar and colleagues has quantified naive CD8 ϩ T cells and showed that their frequencies can differ broadly, even more than 10-fold, among different specificities, and that this variation can account for a swifter response, as measured by the timing of the peak response, and may play a role in immunodominance (58) . Assuming again that A and B alleles will be expressed in the same level in the thymus, the diversity, abundance, and affinity of the self-epitopes presented via these molecules might determine the outcome of positive and negative selection, and thus the naive precursor level. However, the net effect is hard to predict. It seems reasonable to think that the higher binding affinity of peptides for HLA-A will allow the complexes they form to be more stable at the cell surface, hence an increased chance of promoting survival during the positive selection, but also of being recognized with too high affinity and inducing deletion. Additionally, taking into account that HLA-B molecules will present a less diverse repertoire of epitopes, but potentially to a higher cell surface density, it is tempting to speculate that they may select for larger epitope-specific clones.
In this study, we showed that the HLA locus more associated with immunodominant T cell responses seems to be, intriguingly, the one exhibiting the least diverse peptide binding repertoire and presenting peptides with a lower average binding affinity. Although one might conclude that features other than epitope diversity and binding affinity might determine immunodominance, we have explored, above, plausible mechanisms on how these traits can still play a major role. More detailed studies, for example, the determination of HLA-A-and HLA-B-restricted T cell precursor frequencies, may resolve this discrepancy.
